Featured
Featured Videos
- Seres Therapeutics, developer of the first microbiome therapy platform
- Ring Therapeutics, a developer of gene therapies based on its commensal virome platform
- Cellarity, which aims to design medicines targeting the full cellular and molecular complexity of disease as opposed to a single molecular target
- Abiologics, a developer of programmable medicines combining generative artificial intelligence and high throughput chemical protein synthesis (it emerged from stealth mode in July)
- Cygnal Therapeutics, now part of Sonata Therapeutics, whose Network Medicines™ reprogram diseased cells to become “coordinators of cure” by releasing a defined array of signals designed to precisely coordinate multicellular networks to drive disease resolution
Avak Kahvejian, PhD, Recounts His Journey from Sequencing Pioneer to Flagship General Partner on “Close to the Edge”
Bye, Bye, Baltimore: GEN’s Takeaways from ASGCT
This issue of GEN appears in the dog days of summer, a time associated with oppressive heat and a dull lack of progress. But our coverage is as lively as ever because there is so much progress to report. Let’s start with our cover story: preclinical models. This space is evolving to address increasing concern over the 3Rs of animal models (replacement, reduction, and refinement), and the emergence of in vitro alternatives such as organ-chips. Another story looks at the industrialization of synthetic biology. To date, synthetic biology has struggled with cost and capacity issues, but it is getting a boost from biofoundries, strain engineering, and precision fermentation. In other stories, we report on AI in drug discovery (AI is streamlining antibody design and balancing antibody attributes) and cancer vaccines (the field may leave its dog days behind by adopting new targeting strategies). Finally, we rank the country’s leading biopharma clusters.